Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, and PD of BMS-986308 in Healthy Participants
NCT04763226Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-986308 in heart failure (HF) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of Adverse Events (AEs) up to 19 days, Incidence of serious adverse events (SAEs) up to 19 days and 15 more. Started Apr 2021; status: completed.
02
Drugs
BMS-986308
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04763226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04763226.